Posted by Michael Wonder on 01 Dec 2021
Huyabio International receives regulatory approval for Hiyasta monotherapy of peripheral T-cell lymphoma In Japan
30 November 2021 - This is the second indication for Hiyasta in Japan following adult T-cell leukaemia/lymphoma.
HUYABIO International today announced the regulatory approval of HBI-8000, brand name Hiyasta, monotherapy for the treatment of relapsed or refractory peripheral T-Cell lymphoma by the Ministry of Health, Labour and Welfare in Japan.
